Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer
暂无分享,去创建一个
S. Beriwal | J. Kelley | R. Edwards | K. Zorn | S. Richard | J. Lesnock | M. Boisen | R. Edwards
[1] S. Beriwal,et al. Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer Is Feasible With High Completion Rates, Low Complications, and Acceptable Patient Outcomes , 2011, International Journal of Gynecologic Cancer.
[2] S. Beriwal,et al. Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. , 2010, Gynecologic oncology.
[3] R. Edwards,et al. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer. , 2009, Gynecologic oncology.
[4] R. Burger,et al. Use of a dummy (pacifier) during sleep and risk of sudden infant death syndrome (SIDS): population based case-control study , 2005, BMJ : British Medical Journal.
[5] M. Markman,et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Robert S Mannel,et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] E. Trimble,et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] E. Venkatraman,et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] B N Bundy,et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Rose,et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Alberts,et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.
[12] E. Partridge,et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.
[13] K. Swenerton,et al. The ‘failure free interval’ defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing , 1991, International Journal of Gynecologic Cancer.
[14] S. Rubin,et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Gore,et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. , 1990, Gynecologic oncology.
[16] C. Stringer,et al. Re-Treatment of Patients With Recurrent Epithelial Ovarian Cancer With Cisplatin-Based Chemotherapy , 1989, Obstetrics and gynecology.
[17] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[18] M. McKay,et al. Cancer of the ovary. , 1994, The New England journal of medicine.
[19] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.